advertisement

WGA Rescources

Baiza-Duran L 1

Showing records 1 to 1 | Display all abstracts from Baiza-Duran L

17051 Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation
Gonzalez JR; Baiza-Duran L; Quintana-Hau J; Tornero-Montano R; Castaneda-Hernandez G; Ortiz M; Alarcon-Oceguera F; Beltran-Loustaunau M; Cortez-Gastelum M; Garciduenas-Mejia J
Journal of Clinical Pharmacology 2007; 47: 121-126

Issue 9-1

Change Issue


advertisement

Oculus